Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Oncological Efficacy and Postoperative Outcomes of Low Grade Mucoepidermoid Carcinoma Treated With Partial Parotidectomy
Ali, Hasnat , Rourk, Katelyn S. , Byrne, Jamie O., Tasche, Kendall K. , Abel, Kathryn M. Van , Moore, Eric J. , Ali, Hawa M , Van Abel, Kathryn M , Yin, Linda X , Price, Daniel L. , Yin, Linda X.

Annals of Otology, Rhinology & Laryngology | May 5, 2025 | Volume: 134 | Issue: 8 | Pages: 606-612

10.1177/00034894251335405 | PMID 40320862 Get It

Objective: To assess the impact of extent of parotidectomy on surgical and oncologic outcomes in low grade mucoepidermoid carcinoma (LGMEC). Methods: A retrospective chart review of all patients undergoing primary surgical treatment for LGMEC from 2000 to 2022 was conducted. Clinical features collected included demographics, facial nerve function, operative techniques, postoperative complications/facial nerve function, and recurrence. Results: 58 patients were included; 10 patients underwent partial parotidectomy (PP), 38 underwent superficial parotidectomy (SP), and 10 underwent near-total/total parotidectomy. PP and SP patients had smaller tumors and more superficial tumors compared to near-total/total parotidectomy group ( P = .03). PP and SP were more likely to have negative margins and less locoregional disease compared to near-total/total parotidectomy patients ( P < .01). Near-total/total parotidectomy were more likely to undergo facial nerve resection (20% vs 0% for PP & SP respectively) ( P = .05). Immediate postoperative facial nerve function was significantly better among PP patients (73% HB I) compared to SP (44% HB I) and near-total/total parotidectomy patients (0% HB I) ( P < .01). Most patients regained their facial nerve function although only 40% of the near-total/total parotidectomy patients had a HB I at the time of last follow up ( P < .01). Patients were followed for a median of 6.2 years, during which only 1 patient (total parotidectomy) had a recurrence. Conclusions: PP offers a safe and effective approach for small LGMEC tumors, ensuring better facial nerve function postoperatively with minimal complications compared to more extensive surgery.
Enhancing the utility of placental pathology reports for clinical use
Santos, Janelle, Szymanski, Linda M. , Enninga, Elizabeth Ann L. , Mcduffie, Molly, Bulawa‐Regner, Lainee A., Cheek‐Norgan, E. Heidi, Lamppa, Julie A., Wick, Myra , Theiler, Regan N. , Bulawa-Regner, Lainee A, Cheek-Norgan, E Heidi, Enninga, Elizabeth Ann L , Norgan, Andrew P. , Mcduffie, Molly

Pregnancy | May 5, 2025 | Volume: 1 | Issue: 3 | Pages: No page available

10.1002/pmf2.70029 | PMID 42597113 Get It

Abstract Obstetric training programs typically offer limited formal education on placental pathology; yet, in practice, obstetric providers are expected to incorporate placental pathology findings into the overall evaluation of obstetric complications. In this narrative review, we briefly review pathology classifications and then delve deeper into pathology findings that may change clinical decision‐making, specifically highlighting pathologic lesions with a recurrence risk and recommended management for subsequent pregnancies. Last, we present specific recommendations on how to improve clinical interpretability and utility of placental pathology reports for obstetrical practice.
Clinical Outcomes of Mitral Regurgitation Severity and Transcatheter Edge‐to‐Edge Repair in Atrial Functional Mitral Regurgitation
Naser, Jwan A. , Massad, Faysal, Borlaug, Barry A. , Simard, Trevor , Siontis, Konstantinos C. , Kennedy, Austin M , Thaden, Jeremy J. , Eleid, Mackram F. , Borlaug, Barry A , Simard, Trevor , Eleid, Mackram F , Naser, Jwan A , Scott, Christopher G. , Michelena, Héctor I. , Pellikka, Patricia A. , Nkomo, Vuyisile T. , Pislaru, Sorin V.

Catheterization and Cardiovascular Interventions | May 5, 2025 | Volume: 106 | Issue: 1 | Pages: 494-503

10.1002/ccd.31567 | PMID 40320723 Get It

ABSTRACT Background Incident atrial functional mitral regurgitation (AFMR) is associated with mortality. Transcatheter edge‐to‐edge repair (TEER) has shown effectiveness in improving MR and symptoms in AFMR, but previous studies lacked comparison to conservative management. We aimed to study the association of AFMR severity and mitral TEER with symptoms, heart failure hospitalizations (HFH) and all‐cause mortality in moderate/severe AFMR. Methods Consecutive adults with moderate/severe AFMR managed conservatively or with TEER 2010−2023 were identified retrospectively. To ensure similar technique in evaluation in the two groups, variables were obtained from the closest transthoracic echocardiogram before TEER in the TEER group. In addition to multivariable analysis, the association of TEER (vs. conservative management) with HFH and mortality was assessed using propensity‐score matched analyses; the propensity score was based on age, sex, EuroSCORE II, effective regurgitant orifice area, integrative MR severity, and NYHA class III/IV (vs. I/II). Results Among 230 patients with moderate/severe AFMR [mean age 77; 56% females], 46 were managed with TEER. Severe (vs. moderate) AFMR was independently associated with baseline NYHA class III/IV (multivariable OR 2.18 [95% CI 1.13−4.26]) and HFH [multivariable HR 2.75 (95% CI 1.25−6.03)] but not mortality ( p = 0.26). TEER improved MR to ≤ moderate in 93% but was not associated with lower HFH or death rates versus conservative management on multivariable or matched analysis. However, 1‐year NYHA improved more with TEER versus conservative management in patients with baseline NYHA class III/IV (62% vs. 27%, p = 0.03). Rhythm control was associated with improved survival (HR 0.38 [0.15−0.98]). Conclusions AFMR severity was associated with symptoms and HFH but not mortality. MR severity and NYHA class improved with TEER, but the association of TEER with HF hospitalizations or death remains unproven. Randomized studies are needed to evaluate the potential role of TEER and rhythm control on outcomes in AFMR.
Twenty Years of the Paediatric Radiation Oncology Society
Gaze, Mark N. , Beldjoudi, Guillaume , Freeman, Carolyn, Indelicato, Daniel J. , Kortmann, Rolf‐Dieter , Lassen, Yasmin, Mahajan, Anita , Marcus, Karen J. , Njiraini, Pauline Njoki , Parkes, Jeannette , Qureshi, Bilal Mazhar , Robles, Beatriz García, Seiersen, Klaus , Indelicato, Daniel J , Njiraini, Pauline Njoki , Parkes, Jeannette , Paulino, Arnold C , Qureshi, Bilal Mazhar , Gaze, Mark N , Carrié, C. , Kristensen, Ingrid Fagerström , Laprie, Anne , Paulino, Arnold C. , Robles, Beatriz García, Timmermann, Beate , Esiashvili, Natia

Pediatric Blood & Cancer | May 5, 2025 | Volume: 72 | Issue: 7 | Pages: No page available

10.1002/pbc.31764 | PMID 40320663 Get It

ABSTRACT In 2005, the Paediatric Radiation Oncology Society (PROS), a multi‐professional association to promote radiotherapy for children and young people, was created. Its mission has been to educate those involved in this field, and to improve the standards of radiation oncology care for children, adolescents, and young adults across the globe, not least in less privileged settings where the majority of the world's children, and most with cancer, live. Through regular congresses, and joint meetings with the International Society of Paediatric Oncology (SIOP), PROS has facilitated a focus on this treatment modality, and advocated on behalf of those who might benefit from it.
Combined Heart and Liver Transplantation in the Failing Fontan: Systematic Review and Single-arm Meta-analysis
Vizentin, Vanessa Karlinski , Bulhões, Elísio , Ameduri, Rebecca , Johnson, Jonathan N. , Karlinski Vizentin, Vanessa, Ferreira Félix, Iuri, Antunes, Vânio , Félix, Iuri Ferreira , Mesquita, Cynthia Florêncio de

Transplantation | May 5, 2025 | Volume: 109 | Issue: 11 | Pages: 1783-1791

10.1097/tp.0000000000005400 | PMID 40320589 Get It

Background. The Fontan procedure has transformed the management of congenital heart defects characterized by single ventricle physiology, yet it predisposes individuals to Fontan-associated liver disease. Combined heart and liver transplantation (CHLT) emerges as a therapeutic option, but evidence of its efficacy and safety remains limited. This study aimed to comprehensively evaluate CHLT in Fontan patients, focusing on patient characteristics, perioperative outcomes, and posttransplant morbidity and mortality. Methods. Following Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, a systematic search of PubMed, Embase, and the Cochrane Central Register of Controlled Trials was conducted. Studies meeting the intervention of CHLT in Fontan patients were included, and data were collected and synthesized using proportion meta-analysis techniques. Statistical analysis was carried out using R software. Results. Four studies met inclusion criteria, comprising 67 Fontan patients undergoing CHLT. All included studies were observational retrospective cohorts performed in the United States. The 1-y survival rate post-CHLT was 88% (95% confidence interval [CI], 70%-98%). Liver graft rejection rates were low, 4% (95% CI, 0%-22%), and no heart graft rejection greater than mild was reported. Postoperative complications included acute kidney injury 75% (95% CI, 50%-93%), temporary dialysis 27% (95% CI, 9%-51%), neurologic events 7% (95% CI, 0%-26%), infection 23% (95% CI, 3%-55%), and unplanned medical procedures 40% (95% CI, 23%-59%). Conclusions. CHLT in Fontan patients demonstrates promising survival rates, but graft rejection and postoperative complications pose challenges. The rate of renal complications is particularly notable and requires further evaluation. Future research should prioritize comparative different management strategies and long-term follow-up to refine protocols and optimize outcomes.
Tumor-Treating Fields Alter Nanomechanical Properties of Pancreatic Ductal Adenocarcinoma Cells Co-Cultured with Extracellular Matrix
Kulkarni, Tanmay , Banik, Sreya, Mukhopadhyay, Debabrata , Babiker, Hani M. , Bhattacharya, Santanu , Babiker, Hani , Mukhopadhyay, Debabrata , Bhattacharya, Santanu , Banik, Sreya

Journal of Functional Biomaterials | May 4, 2025 | Volume: 16 | Issue: 5 | Pages: 160

10.3390/jfb16050160 | PMID 40422825 Get It

Tumor-Treating Fields (TTFields), a novel therapeutic avenue, is approved for therapy in Glioblastoma multiforme, malignant pleural mesothelioma, and metastatic non-small cell lung cancer (NSCLC). In pancreatic ductal adenocarcinoma (PDAC), several clinical trials are underway to improve outcomes, yet a significant knowledge gap prevails involving the cell-extracellular matrix (ECM) crosstalk. Herein, we hypothesized that treatment with TTFields influence this crosstalk, which is reflected by the dynamic alteration in nanomechanical properties (NMPs) of cells and the ECM in a co-culture system. We employed an ECM gel comprising collagen, fibronectin, and laminin mixed in 100:1:1 stoichiometry to co-culture of Panc1 and AsPC1 individually. This ECM mixture mimics the in vivo tumor microenvironment closely when compared to the individual ECM components studied before. A comprehensive frequency-dependent study revealed the optimal TTFields frequency to be 150 kHz. We also observed that irrespective of the ECM’s presence, TTFields increase cell membrane stiffness and decrease deformation several-folds in both Panc1 and AsPC1 cells at both 48 h and 72 h. Although adhesion for AsPC1 decreased at 48 h, at 72 h it was observed to increase irrespective of ECM’s presence. Moreover, it significantly alters the NMPs of ECM gels when co-cultured with PDAC cell lines. However, AsPC1 cells were observed to be more detrimental to these changes. Lastly, we attribute the stiffness changes in Panc1 cells to the membrane F-actin reorganization in the presence of TTFields. This study paves a path to study complex PDAC TME as well as the effect of various chemotherapeutic agents on such TME with TTFields in the future.
Deep Learning-Based Synthetic CT for Personalized Treatment Modality Selection Between Proton and Photon Therapy in Thoracic Cancer
Zhu, Libing , Yu, Nathan Y. , Tegtmeier, Riley C. , Ashman, Jonathan B. , Duan, Jingwei , Chen, Quan , Rong, Yi , Chen, Quan , Anand, Aman, Duan, Jingwei , Anand, Aman Raj

Cancers | May 4, 2025 | Volume: 17 | Issue: 9 | Pages: 1553

10.3390/cancers17091553 | PMID 40361479 Get It

Objectives: Identifying patients’ advantageous radiotherapy modalities prior to CT simulation is challenging. This study aimed to develop a workflow using deep learning (DL)-predicted synthetic CT (sCT) for treatment modality comparison based solely on a diagnostic CT (dCT). Methods: A DL network, U-Net, was trained utilizing 46 thoracic cases from a public database to generate sCT images predicting planning CT (pCT) scans based on the latest dCT, and tested on 15 institutional patients. The sCT accuracy was evaluated against the corresponding pCT and a commercial algorithm deformed CT (MdCT) based on Mean Absolute Error (MAE) and Universal Quality Index (UQI). To determine advantageous treatment modality, clinical dose-volume histogram (DVH) metrics and Normal Tissue Complication Probability (NTCP) differences between proton and photon treatment plans were analyzed on the sCTs via concordance correlation coefficient (CCC). Results: The AI-generated sCTs closely resembled those of the commercial deformation algorithm in the tested cases. The differences in MAE and UQI values between the sCT-vs-pCT and MdCT-vs-pCT were 19.38 HU and 0.06, respectively. The mean absolute NTCP deviation between sCT and pCT was 1.54%, 0.21%, and 2.36% for esophagus perforation, lung pneumonitis, and heart pericarditis, respectively. The CCC between sCT and pCT was 0.90 for DVH metrics and 0.97 for NTCP, indicating moderate agreement for DVH metrics and substantial agreement. Conclusions: Radiation oncologists can potentially utilize this personalized sCT based approach as a clinical support tool to rapidly compare the treatment modality benefit during patient consultation and facilitate in-depth discussion on potential toxicities at a patient-specific level.
Programmed cell death protein 1 (PD-1) blockade regulates skeletal remodeling in a sex- and age-dependent manner
Joseph, Gwenyth J., Vecchi, Lawrence A., Kane, Jeremy, Durdan, Margaret , Hill, Paige, McAdoo, Ashtyn, Kell, David, Searcy, Madeline B, Nyman, Jeffry S. , Weivoda, Megan , Johnson, Rachelle W. , Weivoda, Megan M, Johnson, Rachelle W , Uppuganti, Sasidhar , Hill, Paige, Tanaka, Hidenori , Kell, David M. , Chen, Wei , Rosenthal, Eben L. , Harrison, David G.

Journal of Bone and Mineral Research | May 3, 2025 | Volume: 40 | Issue: 8 | Pages: 950-964

10.1093/jbmr/zjaf055 | PMID 40318222 Get It

Abstract Immune checkpoint inhibitors (ICIs) block immunoregulatory receptor-ligand interactions and robustly increase survival of cancer patients but frequently result in immune-related adverse events (irAEs). While rheumatologic toxicities are commonly reported as irAEs, the effect of immune checkpoint blockade on the underlying mechanisms of ICI-induced fractures and bone loss is controversial, with reports of both positive and negative effects on bone mass in preclinical models. However, no previous reports have investigated the impact of ICIs on females or aged mice, or on fracture risk in either sex. We report that global deletion of programmed cell death protein 1 (PD-1) broadly results in bone loss in skeletally mature male and female PD-1−/− mice, with a sexually divergent phenotype in adolescent mice, decreased bone strength in adult males and young females, and expansion of multiple T cell subsets in the bone marrow. In a model of pharmacologic PD-1 blockade, administration of α-PD-1 reduced bone mass, expanded multiple T cell subsets in the bone marrow, and increased osteoclast activity and resorptive capacity. T cell deficient mice were resistant to osteoclast-mediated bone loss following α-PD-1 therapy, suggesting that T cells in the bone marrow are necessary for bone loss in the setting of ICI therapy. These findings may be leveraged to identify patients at greater fracture risk following ICI therapy due to enrichment of effector T cell populations in the bone marrow.